Mumbai, India, March 24, 2021: LupinLife, consumer healthcare business of global pharma major Lupin Limited, today announced its association with the Uttarakhand Police for Kumbh Mela 2021. During the Kumbh, LupinLife will provide five lakh LupiSafe hand sanitizers to policemen and frontline workers deployed at strategic locations – parking spots, food centres, health centres and bathing areas – in Hardwar to keep them safe from COVID-19 and other infections.
LupinLife will also provide brochures to the tourists to ensure they have access to critical information. These include road traffic routes to and from adjoining cities, major bathing dates, demarcated parking spots, etc to help tourists navigate their way easily. The brochures will be distributed at major parking spots to the tourists entering Hardwar by car.
According to Mr. Sanjay Gunjyal, Inspector General of Police, Kumbh Mela-2021, Haridwar, Uttarakhand, “We appreciate the compassion and support offered by Lupin in keeping police personnel and frontline workers safe during Kumbh Mela. While we are taking adequate safety measures, it is heartening that Lupin is supporting our efforts to keep police personnel and frontline workers safe in the line of duty.”
Mr. Rajeev Sibal, President, India Region Formulations, Lupin Limited said, “We at Lupin feel a deep responsibility to help address this unprecedented crisis by tirelessly dedicating our support to the healthcare professionals and frontline workforce. At Kumbh too, we are proud to support policemen and frontline workers by providing them necessary protection as they tirelessly manage this mega event.”
Commenting on the association, Mr. Anil Kaushal – Head of LupinLife Consumer Healthcare said, “The Kumbh Mela is the largest congregation of devotees with millions of tourists participating in this year’s event. We are delighted to partner with Uttarakhand Police who are working tirelessly to manage this mega event successfully. Providing them with LupiSafe is our token of gratitude towards them.”
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. For the nine months ended December 31, 2020, the Company invested 9.8% of its revenues on research and development.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on
For further information or queries please contact –
Head – Corporate Communications
Head – Investor Relations/ Corporate M&A
GM – Corporate Communications